OPEN END TURBO BULL - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 13:25:19 2024-05-20 EDT | ||
| 18.38 EUR | +2.11% |
|
| Current month | +29.87% | ||
| 1 month | +29.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-20 | 18.38 | +2.11% |
| 24-05-17 | 18 | +2.39% |
| 24-05-16 | 17.58 | +0.40% |
| 24-05-15 | 17.51 | +7.09% |
| 24-05-14 | 16.35 | -2.15% |
Delayed Quote Deutsche Boerse AG
Last update May 20, 2024 at 01:25 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KF9XX3 |
| ISIN | DE000KF9XX32 |
| Date issued | 2021-12-21 |
| Strike | 249.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.94 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19 € |
|---|---|
| Lowest since issue | 0.83 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.9
USD
Average target price
462.6
USD
Spread / Average Target
+3.74%
- Stock Market
- Certificates
- Certificat
